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Abstract  
 
Introduzione 
La sclerosi sistemica (SSc) è una malattia multisistemica cronica del tessuto connettivo 
caratterizzata dalla fibrosi progressiva della cute e degli organi interni. Sebbene i 
meccanismi patogenetici coinvolti nella malattia sono poco chiari, è stato dimostrato che i 
pazienti affetti da SSc presentano alti livelli di stress ossidativo (Reactive Oxygen Species 
[ROS])  tale da suggerire un ruolo nella fibrogenesi. In questo studio valutiamo i livelli di 
ROS sia nella cute indurita che quella apparentemente sana dei pazienti affetti da SSc e li 
confrontiamo con dei controlli sani. 
Metodi 
Sono stati arruolati 9 pazienti (4 uomini e 5 donne) con dcSSc soddisfacendo i criteri 
diagnostici (EULAR/ACR) e 7 controlli sani abbinati per età e sesso. L’età media dei 
pazienti era 46±10 anni e la durata media della malattia era 7.5±5 anni. Tutti i pazienti 
erano ANA (Scl-70) positivi. Il coinvolgimento cutaneo è stato valutato con lo score di 
Rodnan modificato (mRSS). Al momento dello studio, da ciascun paziente sono state 
prelevate 2 biopsie cutanei (punch biopsy 4 mm), una da pelle indurita (con mRSS 2-3) e 
un’altra da pelle apparentemente sana (con mRSS 0). Contemporaneamente, sono stati 
prelevati campioni di sangue per l’analisi dello stress nel siero. Per l’analisi dei ROS nella 
cute è stata utilizzata la metodica spettrometrica altamente sensibile EPR (Electron 
Paramagnetic Resonance). Invece, diverse metodiche spettrofotometriche sono stati 
utilizzati per l’analisi dello stress nel siero.  
Risultati 
I livelli dei ROS (mediana e range, in nmol/l/min/mg di peso secco) erano 24.7(10.9-47.0) 
nella cute indurita, 18.7(7.3-34.0) nella cute apparentemente sana e 7.7(3.5-13.6) nella cute 
dei controlli sani. Lo stress era significativamente più alto nei pazienti (sia cute indurita 
che cute apparentemente sana) rispetto ai controlli (p<0.05). Inoltre, la cute indurita 
mostrava livelli di stress più alti della cute apparentemente sana dello stesso paziente 
(p=0.01). lo stress nella cute indurita si correlava con la capacità vitale forzata (FVC) (r= -
0.75, p=0.02) e la velocità di eritrosedimentazione (VES) (r=0.70, p=0.04). Rispetto ai 
controlli, il siero dei pazienti affetti da SSc ha mostrato livelli di acido ascorbico più basso 
(8 [3.8-9.8] vs. 10.5 [9-19.1] mg/L, p=0.004) e livelli di perossidi lipidici più alti (873.5 
[342-1973] vs. 422 [105-576] μmol/L, p=0.004).     
Conclusioni 
I risultati del nostro studio indicano la presenza di alto stress ossidativo sia nella cute 
indurita che in quella apparentemente sana dei pazienti affetti di SSc, con una tendenza più 
alta nella cute indurita. La presenza di alto stress nella cute apparentemente sana può 
indicare un precoce ruolo dello stress nella fibrogenesi. Per approvare quest’ipotesi 
necessitiamo di studi longitudinali prospettici. 
 
Abstract 
 
Background and Objectives 
Systemic Sclerosis (SSc) is a chronic multisystemic connective tissue disease characterized 
by progressive fibrosis affecting skin and internal organs. Despite serious efforts to unveil 
the pathogenic mechanisms of SSc, they are still unclear. High levels of Reactive Oxygen 
Species (ROS) in affected patients have been shown, and ROS are suggested to play a role 
in fibrosis pathogenesis. In this study we evaluate ROS levels in non-fibrotic and fibrotic 
skin of patients with SSc and we compare them with those obtained from healthy controls.  
Patients and Methods 
We enrolled 9 SSc patients fulfilling the EULAR/ACR classification criteria and 7 healthy 
controls.  Patients included were 4 men and 5 women with mean age of 46 ±10 yrs.  
Controls were matched by sex and age.  All patients were  affected by  diffuse cutaneous 
form of SSc and the ANA pattern  anti-Scl70. Mean disease duration was 7.5±5  yrs. Skin 
involvement was evaluated by modified Rodnan Skin Score (mRSS).  Skin samples (4mm 
punch biopsy) were taken from fibrotic skin and non-fibrotic skin of patients and from 
healthy controls as well. To detect ROS, specimens were analyzed immediately after 
sampling by electron paramagnetic resonance spectroscopy. Blood samples have been 
drawn from all patients and controls to assess oxidative stress biomarkers. 
Results 
ROS levels (expressed as median and range, unit of measurement was nmol/l/min/mg of 
dry weight) were 24.7 (10.9– 47.0) in fibrotic skin, 18.7 (7.3–34.0) in non-fibrotic skin and 
7.7 (3.5–13.6) in healthy controls skin. ROS levels in Fibrotic and Non-fibrotic skin of SSc 
patients were significantly higher than in Healthy Controls (p=0.002 and p=0.009, 
respectively). ROS levels in fibrotic skin were raised in comparison to non-fibrotic skin, 
when samples related to each patient were compared (p=0.01). ROS levels in fibrotic skin 
were correlated with forced vital capacity (r= -0.75, p=0.02) and erythrocyte sedimentation 
rate (r=0.70, p=0.04). All other clinical and lab parameters showed no significant 
correlation. When compared to controls, blood from SSc patients showed lower ascorbate 
(vitamin C) levels (8 [3.8-9.8] vs. 10.5 [9-19.1] mg/L, p=0.004) and higher lipid peroxides 
(873.5 [342-1973] vs. 422 [105-576] μmol/L, p=0.004).   
Conclusion 
Our results indicate the presence of high oxidative stress both in non-fibrotic skin and 
fibrotic skin of SSc patients, but with higher tendency in the latter. Raised ROS levels in 
non-fibrotic skin of SSc patients might be a hint of early involvement in skin fibrogenesis.  
However, a longitudinal prospective study is necessary for such proof. 
 
 
 
 
 
Highlights 
 
• Skin of patients with dcSSc, either fibrotic or “apparently” normal skin showed higher 
ROS levels as compared to healthy controls skin. 
• ROS levels were higher in Fibrotic skin than in non-fibrotic skin of patients. 
• ROS levels in fibrotic skin of dcSSc patients were positively correlated with ESR and 
negatively correlated with FVC.  
• Blood from patients with dcSSc had lower ascorbate levels and higher lipid peroxides 
levels as compared to healthy controls. 
 
 
 
This original research has been published in the Free Radical Biology and Medicine 
Journal “K. Bourji et al. / Free Radical Biology and Medicine 87 (2015) 282-289”. 
 
 
Introduction 
 
Systemic Sclerosis [SSc] is a chronic multisystem connective tissue disease characterized 
by progressive fibrosis of many organs of the body [1, 2].  Although skin involvement 
forms the hallmark of SSc, internal organ damage due to fibrosis results in mortality for 
this disease [3].  Even though the pathogenesis of SSc is unclear, fibrosis is proposed to be 
the outcome of a combination of autoimmune and proliferative/obliterative vasculopathy 
mechanisms [4-6].  Beside these pathogenetic pathways proposed to explain fibrosis, a role 
of oxidative stress in the pathogenesis of SSc has also been suggested [7, 8]. 
Under different endogenous or exogenous stresses, atoms with unpaired electrons called 
Free Radicals are generated. The 2 major types of Free Radicals formed from Oxygen and 
Nitrogen are, Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) [9]. 
Both ROS and RNS can cause oxidative damage to DNA, lipids, carbohydrates and 
proteins in cells which leads to structural damage and ultimately results in cellular damage 
[10, 11]. To counteract the oxidative damage caused by ROS and RNS, the cells have 
developed a defense mechanism called antioxidants. An imbalance between the elevated 
levels of ROS/RNS and/or the impaired function of the antioxidant defence system is 
known as oxidative stress [8].  In SSc, elevation of oxidative stress “markers” or alteration 
of antioxidant mechanisms have been described by many investigators [8, 12-18].  
 
Oxidative stress markers in plasma were found to be elevated in patients with diffuse 
cutaneous SSc (dcSSc) compared to controls, and the presence of anti-Scl70 in these 
patients was associated with higher stress [12]. ROS levels, in particular superoxide levels, 
were higher in dermal fibroblasts obtained from the skin of patients with dcSSc compared 
to normal cells [13].  On the other hand, some investigators have shown an abnormal 
antioxidant status in scleroderma patients, demonstrating either high detoxifying enzymes 
(Erythrocyte glutathione transferase, eGST) [14] or high Total Antioxidant Power (TAP) 
[15] in these patients. Conversely, non-enzymatic antioxidants such as ascorbic acid 
(vitamin C), α-tocopherol, β-carotene, and selenium were also shown to be reduced in 
plasma of patients with SSc [8, 16].  A role of anti-detoxifying-enzymes antibodies has 
also been proposed. The anti-Prx I (Peroxiredoxin I) antibodies were increased in both 
limited and diffuse SSc and in other autoimmune diseases [17].  The same group also 
showed that anti-MSRA (Methionine Sulfoxide reductase A) antibodies were raised in SSc 
patients and were correlated with disease severity [18].   
Despite the existence of oxidative stress in patients with SSc, the stage of the disease in 
which ROS/RNS manifests is unknown. We hypothesize that ROS levels are elevated early 
in the skin of SSc patients.  In this study we assess ROS levels in non-fibrotic and fibrotic 
skin of patients with SSc. 
 
Materials and Methods 
 
Patients and Populations 
In our study we enrolled adult patients, over 18 years old at baseline, with diffuse 
cutaneous SSc (dcSSc) satisfying the recent ACR/EULAR criteria for Systemic Sclerosis 
[19]. All patients were diagnosed for SSc and subsequently followed in outpatient regime 
at the Division of Rheumatology in Hôpital de Hautepierre -Les Hôpitaux Universitaires de 
Strasbourg (France).  Patients with limited cutanaous SSc, scleroderma-like conditions, 
localized Scleroderma or overlapping syndromes (SSc associated rheumatoid arthritis, 
inflammatory myopathies and/or systemic lupus erythematosus) have been excluded.  
Patients and controls with a recent history of smoking (in the last 3 months) or infections 
(in the last 4 weeks) were excluded as well. The protocol of our study was approved by our 
institutional review board.  After a detailed explanation of study endpoints, study 
procedures and possible risks, informed consents were obtained from all patients and 
healthy volunteers according to the declaration of Helsinki. 
 
 
Clinical and Laboratory data 
Paper and digital records of all patients have been reviewed retrospectively at the moment 
of the study and only last follow-up values have been considered.  Clinical data gathered 
for this study included, history of SSc in terms of date of first Raynaud phenomenon (RP) 
and date of first non-Raynaud sign of disease, actual presence or absence of RP, digital 
ulcers (DU), dysphagia, gastro-esophageal reflux symptoms (GERD), dyspnea (NYHA 
classification).  Echocardiographic assessment for all patients has been performed, looking 
for the left ventricle ejection fraction (EF), right ventricle dilation, systolic pulmonary 
artery pressure (PAPs) and pulmonary arterial hypertension (PAH) that was defined as a 
mean pulmonary artery pressure greater than 25 mmHg, with a pulmonary capillary wedge 
pressure of less than 15 mmHg, and a pulmonary vascular resistance greater than three 
Wood units [20].  Pulmonary functional tests (PFTs), forced vital capacity (FVC), 
diffusion capacity to carbon monoxide (DLCO), forced expiratory volume during the first 
second (FEV1), were evaluated as well.   Standard laboratory parameters in study included, 
antinuclear antibody pattern (ANA), markers of inflammation (ESR - erythrocyte 
sedimentation rate, CRP - C reactive protein), serum creatinine levels (Cr). 
 
Skin Biopsy 
Skin punch biopsies of 4mm diameter have been performed in this study [21].  Based on 
the modified rodnan skin score (mRSS) that assesses the thickness of the skin by palpation 
of 17 body areas on a 0 to 3 scale, sites of biopsies were chosen [22]. Chosen biopsy sites 
were marked by surgical marker then skin antiseptic and local anesthetic (Lidocaine 1%) 
were applied.  In patients with dcSSc, first punch biopsy was taken from apparently normal 
skin (mRSS 0) and a second sample from a fibrotic skin (mRSS 2-3).  According to the 
skin score, all samples from normal skin have been sampled from patient’s arms (right or 
left) while samples from fibrotic skin were taken from their forearms (right or left).  On the 
other hand, healthy volunteers had only one biopsy taken from the arm or the thigh, 
considering patient’s will.  Each skin punch extended into subcutaneous fat in order to 
include all cutaneous layers.  Each specimen was put in an individual tube containing 
Krebs HEPES Buffer (see below) placed on ice, and each tube was labeled by patient’s 
name, date of birth, date, time of sampling and site of sampling.  Finally, simple non-
absorbable suture was performed for closure. 
 
Determination of ROS formation by Electron Paramagnetic Resonance [23] 
Unpaired electrons can absorb electromagnetic radiation energy and move between energy 
levels when stimulated by an electromagnetic field.  This absorption can be recorded by 
electron paramagnetic resonance (EPR) spectrometry. While unpaired electrons of ROS are 
very short lived, and therefore difficult to detect, they can form stable adducts with 1-
hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine hydrochloride (CMH), a 
specific spin probe which act as a “spin trap”. These adducts yield specific spectra when 
subjected to EPR spectroscopy. 
Skin biopsies were prepared under biomicroscope optical inspection aided by using petri 
dishes with black bottoms. When present, hypodermal tissue was removed, samples were 
cut in ten pieces and washed twice with the Krebs HEPES Buffer (NaCl 99 mM; KCl 4.69 
mM; CaCl2 2.5 mM; MgSO4 1.2 mM; NaHCO3 25 mM; KH2PO4 1.03mM; D(+)Glucose 
5.6 mM; Na-hEPES 20 mM; pH 7.4) containing 25 µmol/L deferoxamine and 5 µmol/L 
diethyldithiocarbamate (DETC) to minimize CMH auto-oxidation. Following which, the 
samples were incubated in a plate at 37°C with the spin probe CMH (200µM) for 30 
minutes under 20 mmHg of oxygen partial pressure (in order to be under physiological 
conditions) using Gas-Controller (Noxygen Sciences Transfer, Elzach, Germany). The 
reaction was stopped by placing the plate on ice. A volume of 40 μl of supernatant was 
injected in a disposable capillary tube, and placed in Bench Top EPR spectrometer E-
SCAN (Bruker, Germany) at 15°C. Detection of ROS unpaired electron was conducted 
under the following EPR settings: centre field 3461.144g, microwave power 21.85mW, 
modulation amplitude 2.40g, sweep time 5.24 sec (10 scans), sweep width 60g, number of 
lag curve points 1. The amplitude of the signal was measured, and the concentration of 
CM-radical was determined by calibration with standard concentrations of the radicals 
CM∙. After the measurement, the samples were dried for 15 minutes at 150°C, and O2-.  
Production was expressed in nM per minute per milligram of dry weight (nM/min/mg). 
 
Blood redox imbalance biomarkers 
Venous blood samples were drawn on EDTA or Na-heparin as anticoagulant or clot 
activating gel according to the investigated parameter. Blood samples were immediately 
centrifuged on site and plasma or sera were frozen as aliquots on ice packs coming from -
80°C freezer and placed in a refrigerating box. For ascorbate (vitamin C), 0.5 ml plasma 
was immediately transferred to ice-cold tubes containing 0.5 ml of 10% metaphosphoric 
acid. The whole mixture was frozen on dry ice. Analyses were performed by a 
spectrophotometric method using the reduction of 2,6-dichlorophenolindophenol (Perkin 
Elmer Lambda 40, Norwalk, USA) [24]. Plasma vitamin E (α- and γ-tocopherols), β-
carotene, and ubiquinone were assayed by HPLC procedure (Alliance, Waters, USA) 
coupled with a diode array detector (PDA 2996, Waters, USA) [25] using Chromsytems 
kits (32 000, 34 000, and 68 000). Thiol proteins were detected according to Ellman’s 
method [26]. The GSH/GSSG ratio (GSH = reduced glutathione and GSSG = oxidized 
glutathione), as marker of oxidative stress, was determined in whole EDTA blood by the 
GSH/GSSG-412 kit (Bioxytech, Oxis International Inc., Portland, WA, USA). 
The analysis of lipid peroxides (ROOH) as marker of oxidative damage to lipids was 
performed in plasma (EDTA blood) with the commercial kit (Oxystat, Biomedica Gruppe, 
Wien, Austria). Briefly, the peroxide (–OOH) concentration was determined 
spectrophotometrically by reaction of the biological peroxides with peroxidase and a 
subsequent colour reaction using 3,3′,5,5′-tetramethylbenzidine as substrate. The titre in 
free antibodies (IgG) against oxidized lowdensity lipoprotein (Ab-Ox-LDL) was assessed 
with a commercial enzyme immunoassay (Biomedica Gruppe) using Cu2+ oxidized LDL 
as antigen. 
 
Statistical analysis 
Mean ± SD, median (range) or percentages were used to report results. Analysis of 
variance (ANOVA) was performed using Kruskall Wallis test. Wilcoxon signed rank test 
was used to compare two related samples. Correlations between variables were evaluated 
by either Spearmen test or Mann Witney test depending on variable type (nominal or 
continuous). Results with p values < 0.05 were considered statistically significant.  
 
Results 
 
Clinical and laboratory assessment 
Patients group included 9 patients with dcSSc, 5 females (55%) and 4 males (45%) with 
mean age of 46 ± 10 years. Controls group included 7 healthy volunteers matched by age 
and sex. 
Among patients’ group, mean duration of the disease (time from first non-Raynaud sign) 
was 7.5 ± 5 years while mean duration of Raynaud (time from first Raynaud episode) was 
9.7 ± 6.7 years.  At the moment of biopsies, five patients (55%) out of 9 had active digital 
ulcers, 4 of them had less than 3 ulcers and one patient had 5 ulcers.  Pitting scars were 
present in 8 patients (89%).  Median mRSS of SSc patients was 18 (11-40). 
Among the 9 patients, only 1 patient had severe dyspnea (NYHA class IV) and 1 patient 
had a moderate dyspnea (NYHA class III), the rest of patients had milder dyspnea (2 
patients were in NYHA class I, 5 patients were in class II). On transthoracic 
echocardiogram assessment, the patient with severe dyspnea had PAH, with PAPs of 87 
mmHg with moderate to severe right ventricular dilation, the remainder 8 patients had 
normal sPAP values with mean sPAP of 25.1 ± 3.2 mmHg. Where the patient with 
moderate dyspnea but without PAH had heart failure with left ventricular ejection fraction 
of 40%, the remainder 8 patients had normal EF% with mean EF% of 66.1 ± 6.4 %. PFTs 
showed abnormal reduction of DLCO% in all patients, FVC was reduced in 4 patients and 
FEV1 was reduced in 2 patients (80% predicted has been used as cut off for identifying 
abnormal results).  Means of % DLCO, VC and FEV1 were 51.1 ± 22.9, 77.7 ± 23.2, 75.6 
± 19.4; respectively.  Four patients (45%) referred to have mild to moderate dysphagia, and 
8 patients (89%) had GERD symptoms.   
All patients had positive ANA with anti-Scl70 specificity, evaluated by indirect 
immunofluorescence (IIF) on HEp-2 cells.  Serum creatinine levels were normal in all 
patients.  Seven patients (77%) had increased ESR and 5 patients (55%) had increased 
CRP levels.  Means of serum Creatinine, ESR and CRP were 60.6 ± 12 μmol/l (n.v. 45-
111), 26.3 ± 15.5 mm/h (n.v. <9, first hour), 14 ± 12.5 mg/l (n.v. <4); respectively. (table 
1)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Table. 1  Demographic, clinical, instrumental and laboratory findings 
Abbreviations: RP, Raynaud phenomena; DU, digital ulcers; total mRSS, total modified Rodnan Skin Score; NYHA class, New York Heart Association functional classification of 
heart failure; LVEF, left ventricular ejection fraction; sPAP, systolic pulmonary artery pressure; RV, right ventricle; GERD, gastroesophageal reflux disease; DLCO, diffusing lung 
capacity for carbon monoxide; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; Creat, serum creatinine (n.v 45-1 µmol/l );  ESR, erythrocyte sedimentation rate 
(n.v < 9 mm/h;1st hour); CRP, C-reactive protein(n.v <4 mg/l). Grade: mild (1), moderate (2), severe (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROS in skin and clinical correlations 
Skin specimen of each subject in this study was analysed for ROS expression by using 
electron paramagnetic resonance (EPR) spectrometry (figure 1). Results expressed as ROS 
levels per milligram of dry weight of specimen. In patients with dcSSc, median ROS 
production in fibrotic skin was 24.7 (10.9 - 47.0) nM/min/mg and median ROS production 
in non-fibrotic skin was 7.7 (3.5–13.6) nM/min/mg. In control group of healthy volunteers, 
median skin ROS production was 7.7 (3.5–13.6) nM/min/mg. (table 2)  By comparing 
Pt. 
 
age 
(yrs) 
Sex disease 
duration (yrs) 
RP  DU (nb) pitting 
scars 
total 
mRSS 
NYHA 
class (I-
IV) 
LVEF 
(%) 
sPAP 
(mmHg) 
RV 
dilation 
(grade) 
dysphagia 
(grade) 
GERD DLCo 
(%) 
FVC 
(%) 
FEV1 
(%) 
Creat  ESR  CRP  
1 68 M 1 yes No no 11 2 73 27 no no no 33 71 83 82 40 32 
2 39 M 8 yes No yes 15 1 68 23 no no yes 45 69 81 56 34 3 
3 43 F 2 yes yes (1) yes 15 2 68 27 no no yes 76 107 80 61 2 2 
4 45 F 12 yes yes (2) yes 14 2 62 27 no no yes 73 98 87 64 20 2 
5 49 M 3 yes yes (5) yes 40 3 40 18 yes (2) yes (1) yes 33 48 52 55 51 32 
6 52 M 10 yes yes (2) yes 19 4 75 87 yes (3) yes (1) yes 11 42 40 74 25 24 
7 35 F 6 yes yes (1) yes 20 2 60 25 no yes (1) yes 55 83 80 62 17 4,2 
8 48 F 6 yes No yes 16 2 56 28 no yes yes 55,7 77 72 42 37 16 
9 39 F 20 yes No yes 12 1 67 26 no no yes 79 105 106 50 11 11,5 
ROS levels between fibrotic skin of scleroderma patients and skin from healthy controls, 
these levels were significantly higher among fibrotic skin (p=0.002).  Similarly, non-
fibrotic skin of scleroderma patients also showed significantly higher levels of ROS when 
compared to controls (p=0.009) (figure 2). Moreover, comparing samples from fibrotic 
skin to samples from non-fibrotic skin of each patient, ROS levels were higher in fibrotic 
skin (p=0.01) (figure 3). Correlations between ROS levels and every clinical, instrumental 
and laboratory variable have been assessed. However, only FVC and ESR were found to 
correlate with ROS levels in fibrotic skin of SSc patients (r= -0.75, p=0.02) and (r=0.70, 
p=0.04); respectively. (figures 4,5). No correlations were found between ROS levels in 
non-fibrotic skin of patients and clinical, instrumental or laboratory variables.  
 
 
 
 
 
 
 
 
 
Table. 2  ROS levels in skin biopsies  
patients Non-fibrotic skin 
(mRSS 0) 
Fibrotic skin (mRSS 
2-3) 
controls Control skin 
1 14,4 24,7 1 13,6 
2 33 47 2 10,1 
3 7,3 11 3 7,7 
4 10,9 10,9 4 8,7 
5 30,9 37,2 5 6,8 
6 12,8 31,2 6 7,1 
7 18,7 20,5 7 3,5 
8 34 38,3 - - 
9 20,5 19,7 -  -  
Median (range) 18.7 (7.3 – 34) 24 (10.9 – 47)   7.7 (3.5 – 13.6)  
Data are in nM per minute per milligram of dry weight (nM/min/mg). 
 
 
 
 
 
 
 
Fig.1 Representative EPR signal in control (A), SSc non fibrotic skin (B) and SSc fibrotic 
skin (C). 
 
 
Fig.2  Reactive Oxygen Species (ROS) levels 
in controls skin and in patients skin (fibrotic 
skin and non-fibrotic skin), **p=0.009, 
***p=0.002. 
 
 
 
 
 
 
Fig.3  Comparison of ROS levels between 
matched samples (Wilcoxon signed rank test), 
*p=0.01. 
 
 
 
Fig.4 Correlation between Erythrocyte 
Sedimentation Rate (ESR) and ROS levels in 
fibrotic skin of patients. 
 
 
 
 
                                      
Fig.5  Correlation between forced vital capacity 
(FVC) and ROS levels in fibrotic skin of 
patients. 
 
 
 
 
Blood redox imbalance biomarkers 
Figure 6 shows the comparison of the levels of the different redox imbalance biomarkers 
assessed in this study between SSc patients and controls. Among the antioxidants, vitamin 
C levels were significantly lower in SSc patients blood compared to controls (8 [3.8-9.8] 
vs. 10.5 [9-19.1] mg/L, p=0.004).  Lipid peroxides, markers of oxidative damage to lipids, 
were significantly higher among SSc patients (873.5 [342-1973] vs. 422 [105-576] μmol/L, 
p=0.004). Although lacking a strong significance, GSH/GSSG ratio was lower in SSc 
patients (182 [0.9-466] vs. 430 [0.9-506], p=0.17). 
Moreover, the correlation between ROS levels in the skin and blood redox imbalance 
biomarkers has been studied (figures 7, 8). Vitamin C levels in the blood showed a 
significant negative correlation with ROS levels, whether considering fibrotic (r= -0.74, 
p=0.002) or non fibrotic (r= -0.82, p=0.0003) skin of SSc patients. Another significant 
correlation was found between lipid peroxides and ROS levels, whether considering 
fibrotic (r= 0.76, p=0.001) or non fibrotic (r= 0.77, p=0.001) skin of SSc patients.  
   
 
Fig. 6  Comparison of redox imbalance biomarkers between SSc patients and controls. 
               NS non significant; *** p << 0.05  
 
  
 
Fig. 7 Correlation between vitamin C levels and ROS levels in non fibrotic skin (left) and fibrotic skin (right) of 
patients with SSc and controls. 
 
 
 
Fig. 8 Correlation between lipid peroxides levels and ROS levels in non fibrotic skin (left) and fibrotic skin (right) of 
patients with SSc and controls. 
 
 
 
Discussion  
 
In this study we show the presence of high oxidative stress in the skin of patients with 
dcSSc. We also show that both fibrotic skin “apparently” normal skin of patients with SSc 
have had higher ROS levels when compared to normal skin of healthy volunteers.  
 
Our results are in agreement with previous studies that have also suggested high ROS 
production in patients with SSc using indirect biomarkers. In two separate studies, Ogawa 
et al. highlighted on the presence of two oxidative stress biomarkers in SSc. 8-isoprostane 
(an eicosanoid family member of non-enzymatic origin, produced by random oxidation of 
tissue phospholipids) was found to be significantly elevated in sera of patients with SSc, 
either lcSSc or dcSSc, when compared to normal controls. No differences were found in 8-
isoprostane levels between lcSSc and dcSSc patients. [27] Hsp70, a member of the heat 
shock proteins family, is another sensitive biomarker for oxidative stress, cellular stress 
and tissue injury. This protein was found to be significantly elevated in serum of patients 
with SSc compared to healthy controls with no differences between lcSSc and dcSSc 
patients. [28] The same group have also shown that as a result of oxidative stress, in SSc 
patients with either limited or diffuse form SSc, had elevated total antioxidant power 
(TAP) when compared with healthy controls, with no significant difference between 
limited or diffuse forms [15]. A Mexican study [12] on 28 patients with dcSSc also found 
elevated levels of oxidative stress biomarkers, malondialdehyde, dityrosine and carbonyls 
in serum of dcSSc patients as compared to healthy controls, with asignificant positive 
correlation with uric acid levels in patients with dcSSc. Moreover, the antioxidant capacity 
of plasma (ACP) was lower in dcSSc patients compared to healthy controls.  
 
ROS levels in fibrotic skin of our patients were found to be inversely correlated with FVC 
and positively correlated with ESR in serum, two factors that have been independently 
linked to poor outcome [29, 30]. The negative correlation ROS/FVC has been previously 
shown in Japanese patients [27]. Although correlation does not mean causality, these 
findings corroborated the proposed role of ROS in the development of ILD [31]. Several 
studies have provided evidence of elevated oxidative stress and its biomarkers in patients 
with PAH [32, 33]. On the other hand, ESR together with CRP were shown to be elevated 
in patients with dcSSc with elevated oxidative stress [12], CRP levels were in correlation 
with TAP serum levels in patients with SSc [15].  
 
Our analysis of blood redox imbalance biomarkers showed a significant decrease in 
vitamin C levels and a significant increase in peroxide lipids in patients with SSc when 
compared to healthy controls. These findings are in agreement with earlier studies [8, 16, 
34]. We also showed the presence of a significant correlation between vitamin C and 
peroxide lipids in the serum and ROS levels in the skin regardless of the fibrotic feature of 
the biopsied skin (fibrotic, non fibrotic or control skin). Hence, this latter finding support 
the accuracy of the EPR in determining ROS production in skin biopsies.   
 
This is a proof-of-concept study. To our knowledge, it is the first study to directly analyzed 
ROS production in complete skin samples from patients with dcSSc using EPR protocol 
that preserved essential interactions of the cells with their microenvironment. The hallmark 
of our study is the assessment of different skin phenotypes in the same patient by studying 
fibrotic and non-fibrotic skin zones of patients with dcSSc. However, only two studies 
have shown an important activation relationship between ROS and  fibroblasts isolated 
from skin of patients with scleroderma, Sambo et al. [36] have shown an increase in-vitro 
release of ROS from quiescent scleroderma fibroblasts (in absence of any stimulation). 
Dermal fibroblasts obtained from the forearms of patients with dcSSc were studied by 
Tsou et al. [13], which showed  significant higher levels of superoxide produced by 
patients fibroblasts as compared to normal fibroblasts, and a decrease in superoxide 
production in SSc-fibroblasts in presence of NAC (thiol antioxidant) with a higher thiol 
content in normal fibroblasts as compared to SSc-fibroblasts.   
 
Limitations of the study 
The sample size of study groups might be considered small in terms of reliability and 
validity of our results, however difficulties have been faced to enroll patients with dcSSc, 
as patients were expressing their awareness for prolonged healing time in biopsy site, their 
wide experience with digital ulcers and the difficulties in healing they face explain this 
awareness.  
Another limitation of this study was the subjectivity of choosing site of biopsy and its 
related skin score. For this reason we tried to standardize site of biopsy in patients with 
SSc by sampling the affected skin from forearms and the normal skin from arms patients, 
and the skin score given to those areas was done by the same physician in all patients and 
controls. 
 
Conclusions 
In conclusion, our study confirms the presence of high ROS levels in the skin of patients 
with dcSSc, either in fibrotic or in “apparently” normal skin. Thus, ROS is suggested to 
play an important role in the pathogenesis of fibrosis in scleroderma, a role that could be 
initial or intermediate in terms of disease time line progression considering our finding of 
high ROS levels in “apparently” normal skin of SSc patients. Higher ROS levels in fibrotic 
skin compared to non-fibrotic skin, suggests a possible role of other co-factors to play with 
ROS in fibrosis pathogenesis. However, in order to certify these statements it is necessary 
to assess larger cohort of patients in a longitudinal prospective design, and to measure skin 
oxidative stress in these patients at different moments during their follow up considering 
the clinical progression and skin fibrosis extension in relation to skin biopsy sampling 
sites, together with further molecular intra- and extracellular investigations. 
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